|
Basic Characteristics of Mutations
|
|
Mutation Site
|
T124A |
|
Mutation Site Sentence
|
Interestingly, position 124 had different highly polymorphic mutations in the A1 (T124A) and A6 (T124S) sequences. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
IN |
|
Standardized Encoding Gene
|
gag-pol:155348
|
|
Genotype/Subtype
|
HIV-1 |
|
Viral Reference
|
K03455.1
|
|
Functional Impact and Mechanisms
|
|
Disease
|
HIV Infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
INSTIs |
|
Location
|
Russia |
|
Literature Information
|
|
PMID
|
32752001
|
|
Title
|
Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs
|
|
Author
|
Kirichenko A,Lapovok I,Baryshev P,van de Vijver DAMC,van Kampen JJA,Boucher CAB,Paraskevis D,Kireev D
|
|
Journal
|
Viruses
|
|
Journal Info
|
2020 Jul 31;12(8):838
|
|
Abstract
|
The increasing use of the integrase strand transfer inhibitor (INSTI) class for the treatment of HIV-infection has pointed to the importance of analyzing the features of HIV-1 subtypes for an improved understanding of viral genetic variability in the occurrence of drug resistance (DR). In this study, we have described the prevalence of INSTI DR in a Russian cohort and the genetic features of HIV-1 integrase sub-subtype A6. We included 408 HIV infected patients who were not exposed to INSTI. Drug resistance mutations (DRMs) were detected among 1.3% of ART-naive patients and among 2.7% of INSTI-naive patients. The prevalence of 12 polymorphic mutations was significantly different between sub-subtypes A6 and A1. Analysis of the genetic barriers determined two positions in which subtype A (A1 and A6) showed a higher genetic barrier (G140C and V151I) compared with subtype B, and one position in which subtypes A1 and B displayed a higher genetic barrier (L74M and L74I) than sub-subtype A6. Additionally, we confirmed that the L74I mutation was selected at the early stage of the epidemic and subsequently spread as a founder effect in Russia. Our data have added to the overall understanding of the genetic features of sub-subtype A6 in the context of drug resistance.
|
|
Sequence Data
|
MT382663-MT383070
|